Expression of foxp3 in edited cd34+ cells
US-2024117352-A1 · Apr 11, 2024 · US
Method of producing microglial cells
US2016333316A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016333316-A1 |
| Application number | US-201515110004-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jan 9, 2015 |
| Priority date | Jan 9, 2014 |
| Publication date | Nov 17, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a method of inducing microglia cells from blood cells, comprising culturing the blood cells in the presence of interleukin-34 (IL-34) and granulocyte-macrophage colony stimulating factor (GM-CSF).
First claim
Opening claim text (preview).
1 . A method of inducing microglial cells from blood cells, comprising culturing the blood cells in the presence of interleukin-34 (IL-34) and granulocyte-macrophage colony stimulating factor (GM-CSF). 2 . A method of producing microglial cells, comprising culturing blood cells in the presence of interleukin-34 (IL-34) and granulocyte-macrophage colony stimulating factor (GM-CSF), and collecting microglial cells from the culture. 3 . The method of claim 1 or 2 , wherein the blood cells are human peripheral monocytes. 4 . The method of claim 1 or 2 , wherein a concentration of IL-34 is 1-200 ng/ml. 5 . The method of claim 1 or 2 , wherein a concentration of GM-CSF is 1-200 ng/ml. 6 . A microglial cell obtained by the method claim 1 . 7 . A kit for inducing microglial cells from blood cells, comprising interleukin-34 (IL-34) and granulocyte-macrophage colony stimulating factor (GM-CSF). 8 . A method of screening a therapeutic drug for a psychiatric disease or a neurodegenerative disease, comprising the steps of: causing the microglial cell according to claim 6 to make contact with a candidate substance to measure a cellular activity of the cell; and using the obtained measurement result as an indicator. 9 . The method according to claim 8 , wherein the cellular activity is at least one selected from the group consisting of phagocytosis, proliferation capacity, viability, neurite elongation capability, cytokine production, morphological changes and differentiation capacity. 10 . The method according to claim 8 or 9 , wherein the psychiatric disease or neurodegenerative disease is at least one selected from the group consisting of schizophrenia, mood disorder, dementia, autism, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Huntington's chorea, prion diseases, multiple sclerosis, and physical diseases. 11 . The method according to claim 10 , wherein the physical diseases are autoimmune disorders, atopic disorders or diabetes. 12 . A method of evaluating a responsiveness of a therapeutic drug for a psychiatric disease or a neurodegenerative disease, comprising the steps of: causing the microglial cell according to claim 6 to make contact with a candidate substance to measure a cellular activity of the cell; and using the obtained measurement result as an indicator. 13 . The method according to claim 11 , wherein the cellular activity is at least one selected from the group consisting of phagocytosis, proliferation capacity, viability, neurite elongation capability, cytokine production, morphological changes and differentiation capacity. 14 . The method according to claim 12 , wherein the psychiatric disease or neurodegenerative disease is at least one selected from the group consisting of schizophrenia, mood disorder, dementia, autism, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Huntington's chorea, prion diseases, multiple sclerosis, and physical diseases. 15 . A kit for screening or evaluating a therapeutic drug for a psychiatric disease or a neurodegenerative disease, comprising a microglial cell according to claim 6 . 16 . A pharmaceutical composition for treating a psychiatric disease or a neurodegenerative disease, comprising a microglial cell according to claim 6 .
Assignees
Inventors
Classifications
Anti-Parkinson drugs · CPC title
Drugs for disorders of the nervous system · CPC title
Neurological disorders · CPC title
from monocytes, from macrophages · CPC title
Psychoses; Psychiatry · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016333316A1 cover?
- The present invention provides a method of inducing microglia cells from blood cells, comprising culturing the blood cells in the presence of interleukin-34 (IL-34) and granulocyte-macrophage colony stimulating factor (GM-CSF).
- Who is the assignee on this patent?
- Univ Kyushu Nat Univ Corp
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0645. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Nov 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).